missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 18480508

KIR2DL1/CD158a Antibody (MM0438-11G25), mFluor Violet 500 SE, Novus Biologicals™

Mouse Monoclonal Antibody

Brand:  Novus Biologicals NBP2-11758MFV500

Product Code. 18480508

  • € 629.00 / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

KIR2DL1/CD158a Monoclonal antibody specifically detects KIR2DL1/CD158a in Human samples. It is validated for Western Blot
TRUSTED_SUSTAINABILITY
Specifications

Specifications

KIR2DL1/CD158a
Monoclonal
Western Blot
CD158 antigen-like family member A, CD158a antigen, CD158Ankat1, cl-42, killer cell immunoglobulin-like receptor 2DL1, killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1, killer Ig receptor, killer inhibitory receptor 2-2-1, KIR221, MHC class I NK cell receptor, Natural killer-associated transcript 1, NKAT, NKAT-1, NKAT1KIR-K64, p58 killer cell inhibitory receptor KIR-K64, p58 natural killer cell receptor clones CL-42/47.11, p58 NK cell inhibitory receptor NKR-K6,47.11, p58 NK receptor CL-42/47.11, p58.1, p58.1 MHC class-I-specific NK receptor
0.1 mL
Western Blot
mFluor Violet 500 SE
50mM Sodium Borate
Human recombinant KIR2DL1/CD158a
Primary
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.